News Headlines Article

How this cancer-fighting startup switched gears, landed a big deal and started a clinical trial
San Francisco Business Times

AbbVie in January paid $105 million for an exclusive option to license small Tizona’s experimental cancer-fighting drug, so the results from an early-stage clinical trial started this month are important.